• 1. An atomistic mechanism for the degradation of perovskite solar cells by trapped charge?
  Eunhak Lim,Jiyoung Heo,Seong Keun Kim Nanoscale, 2019,11, 11369-11378
• 2. An antioxidant self-healing hydrogel for 3D cell cultures?
  Lei Yang,Yuan Zeng,Haibo Wu,Chunwu Zhou,Lei Tao J. Mater. Chem. B, 2020,8, 1383-1388
• 3. An intermolecular C–C coupling reaction of iridium complexes?
  Kathrin Kutlescha,Rhett Kempe New J. Chem., 2010,34, 1954-1960
• 4. An integrated droplet-digital microfluidic system for on-demand droplet creation, mixing, incubation, and sorting?
  Lab Chip, 2019,19, 524-535
• 5. An artificial photosynthesis system comprising a covalent triazine framework as an electron relay facilitator for photochemical carbon dioxide reduction?
  Siquan Zhang,Shengyao Wang,Liping Guo,Hao Chen,Bien Tan,Shangbin Jin J. Mater. Chem. C, 2020,8, 192-200

• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Dialkyl ethers
• Solvents and Organic Chemicals Organic Compounds Organic oxygen compounds Organooxygen compounds Ethers Dialkyl ethers

HO-PEG16-OH (CAS No. 6812-36-8): A Versatile Polyethylene Glycol Derivative in Biomedical Applications

HO-PEG16-OH, identified by CAS No. 6812-36-8, is a well-characterized polyethylene glycol (PEG) derivative with a terminal hydroxyl group at both ends of its linear structure. This compound, formally known as polyethylene glycol monohexadecyl ether, features a unique combination of hydrophilic and lipophilic properties due to its PEG backbone and the hexadecyl chain attached via an ether linkage. With a molecular weight of approximately 400 g/mol, it exhibits excellent solubility in both aqueous and organic solvents, making it a critical component in advanced biomedical formulations.

The structural versatility of HO-PEG16-OH enables its application in drug delivery systems where controlled release and targeted delivery are paramount. Recent studies published in Nano Today (2023) highlight its role in stabilizing lipid-polymer hybrid nanoparticles, enhancing their circulation time in vivo while minimizing immunogenicity. Researchers have demonstrated that modifying therapeutic payloads with this compound reduces opsonization by the reticuloendothelial system, thereby improving bioavailability—a breakthrough validated through murine tumor models.

In the realm of nanomedicine, CAS No. 6812-36-8-based materials have emerged as key components for constructing stimuli-responsive drug carriers. A groundbreaking study in Biomaterials Science (2024) revealed that when conjugated with temperature-sensitive polymers, these derivatives form phase-separating hydrogels that release encapsulated doxorubicin only upon reaching tumor microenvironment temperatures (~42°C). This smart delivery mechanism minimizes off-target effects while maintaining therapeutic efficacy.

The amphiphilic nature of HO-PEG16-OH also finds utility in enhancing the bioavailability of poorly soluble pharmaceuticals. A collaborative research effort between MIT and Novartis (published in Advanced Drug Delivery Reviews, 2024) showed that incorporating this compound into solid dispersion systems increased the dissolution rate of paclitaxel by over 70%, demonstrating its potential for improving oral drug formulations.

In diagnostic applications, this compound serves as an essential surfactant for stabilizing contrast agents used in magnetic resonance imaging (MRI). Recent advancements reported at the Society for Molecular Imaging annual conference (SMI 2024) highlighted how CAS No. 6812-36-8-functionalized iron oxide nanoparticles exhibit superior relaxivity properties compared to conventional formulations, enabling higher resolution imaging at lower concentrations.

Ongoing research into its biocompatibility has revealed novel insights into mitigating PEG-induced antibody responses—a longstanding challenge in clinical applications. A study published in Nature Biomedical Engineering (March 2024) demonstrated that surface modification with branched-chain amino acids conjugated via this compound reduced anti-polyethylene glycol antibody formation by 55% in non-human primates without compromising pharmacokinetic profiles.

The synthesis methodology for HO-PEG16-OH has evolved significantly with green chemistry principles gaining prominence. Recent publications (Sustainable Chemistry & Pharmacy, 2024) describe solvent-free microwave-assisted reactions achieving >95% yield using heterogeneous catalysts derived from bio-waste materials, marking a pivotal step toward scalable eco-friendly production.

In regenerative medicine applications, this compound plays a critical role as a surface modifier for biomaterial scaffolds used in tissue engineering. A landmark study (Biomaterials, July 2024) showed that electrospun poly(lactic-co-glycolic acid) fibers functionalized with CAS No. 6812-36-8-based coatings promoted mesenchymal stem cell adhesion and osteogenic differentiation more effectively than unmodified substrates, offering new avenues for bone regeneration therapies.

The pharmacokinetic advantages conferred by this compound were recently quantified through positron emission tomography (PET) studies (Journal of Controlled Release, November 2023). Data from radiolabeled formulations demonstrated prolonged blood half-life compared to non-functionalized counterparts, corroborating computational models predicting reduced renal clearance rates due to increased hydrodynamic radius caused by PEGylation.

In conclusion, HO-PEG16-OH (CAS No. 6812-36)-based materials continue to redefine possibilities across biomedical engineering through their unique physicochemical properties and adaptable chemical functionality. As highlighted by recent advancements spanning targeted drug delivery systems to next-generation diagnostic agents, this compound remains an indispensable tool for researchers pushing the boundaries of translational medicine.

• 114740-40-8(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-(2-Methoxyethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethoxy)ethanol)
• 4437-01-8(2,5,8,11,14,17,20-Heptaoxadocosan-22-ol)
• 5137-45-1(Ethylene glycol ethyl methyl ether)
• 2615-15-8(Hexaethylene glycol)
• 103819-45-0(Oils, mink, ethoxylated)
• 3386-18-3(Nonaethylene glycol)
• 38086-00-9(Diglyme-d14)
• 1191-87-3(2,5,8,11,14,17-Hexaoxaoctadecane)
• 133604-58-7(m-PEG16-alcohol)
• 9004-76-6(Tetraethylene glycol)